The utility of chemotherapy for women who experience a locoregional recurrence after primary treatment of early breast cancer remains an open question. Trial 27-02 is being conducted to determine the effectiveness of cytotoxic therapy for these patients, either alone or in addition to selective use of hormonal therapy and trastuzumab.
This report describes the characteristics of the first 99 patients.
References:
Wapnir IL, Aebi S, Gelber S, Anderson SJ, Láng I, Robidoux A, Mamounas EP, Wolmark N. Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer. Ann Surg Oncol 15:3227-3231, 2008.